background preloader

PF6009 Respiratory

Facebook Twitter

Cystic Fibrosis Therapeutics: The Road Ahead. Ahead of the Curve Seattle Children's Hospital and the University of Washington School of Medicine, Seattle, WA Received 29 June 2012, Accepted 6 July 2012, Available online 16 December 2015.

Cystic Fibrosis Therapeutics: The Road Ahead

BTS/SIGN British guideline on the management of asthma. (*NEW) 2016 Pocket Guide for Asthma Management and Prevention - Global Initiative for Asthma - GINA. Factors that may trigger or worsen asthma symptoms include viral infections, domestic or occupational allergens (e.g., house dust mite, pollens, cockroach), tobacco smoke, exercise and stress.

(*NEW) 2016 Pocket Guide for Asthma Management and Prevention - Global Initiative for Asthma - GINA

These responses are more likely when asthma is uncontrolled. Some drugs can induce or trigger asthma, e.g., beta-blockers, and (in some patients) aspirin or other NSAIDs. Inhaler Technique Videos. Global Initiative for Chronic Obstructive Lung Disease - Global Initiative for Chronic Obstructive Lung Disease - GOLD. Asthma, COPD, and Asthma-COPD Overlap Syndrome - Global Initiative for Chronic Obstructive Lung Disease - GOLD. GOLD documents are protected by copyright.

Asthma, COPD, and Asthma-COPD Overlap Syndrome - Global Initiative for Chronic Obstructive Lung Disease - GOLD

A single copy of this document may be downloaded for your own educational use, but copies may not be made for distribution or posted on a website without authorization from GOLD. A significant proportion of adult patients over age 40 who present with symptoms of a chronic airways disease have features of both asthma and COPD. Several diagnostic terms, most including the word ‘overlap’, have been applied to such patients, and the topic has been extensively reviewed. However, there is no generally agreed term or defining features for this category of chronic airflow limitation, although a definition based upon consensus has been published for overlap in patients with existing COPD.

This document has been developed by the Science Committees of both GINA and GOLD, based on a detailed review of available literature and consensus. 1302. 871. 798. Clinical Review : Cystic fibrosis. Safety, efficacy and convenience of colistimethate sodium dry powder for inhalation (Colobreathe DPI) in patients with cystic fibrosis: a randomised study. + Author Affiliations Correspondence to Dr Antje Schuster, Zentrum für Kinder und Jugendmedizin, Moorenstrasse 5, Düsseldorf 40225, Germany;schuster@med.uni-duesseldorf.de Received 17 April 2012 Accepted 11 October 2012 Published Online First 7 November 2012 Abstract Purpose To assess efficacy and safety of a new dry powder formulation of inhaled colistimethate sodium in patients with cystic fibrosis (CF) aged ≥6 years with chronic Pseudomonas aeruginosa lung infection.

Safety, efficacy and convenience of colistimethate sodium dry powder for inhalation (Colobreathe DPI) in patients with cystic fibrosis: a randomised study

Safety, efficacy and convenience of tobramycin inhalation powder in cystic fibrosis patients: The EAGER trial - Journal of Cystic Fibrosis. Fig. 1 Study design (A) and disposition (B).

Safety, efficacy and convenience of tobramycin inhalation powder in cystic fibrosis patients: The EAGER trial - Journal of Cystic Fibrosis

Fig. 2 Overall efficacy: A) relative change in FEV1% predicted from baseline over three cycles (efficacy population); and B) change from baseline in Pseudomonas aeruginosa sputum density (efficacy population). New pharmacological approaches for cystic fibrosis: Promises, progress, pitfalls. Associate editor: P.

New pharmacological approaches for cystic fibrosis: Promises, progress, pitfalls

Molenaar a Department of Thoracic Medicine, Prince Charles Hospital, Brisbane, Australiab Queensland Children's Medical Research Institute, Brisbane, Australiac Pediatric Pulmonology, Department of Pediatrics, University of Leuven, Leuven, Belgiumd University of Lisboa, Faculty of Sciences, BioFIG — Centre for Biodiversity, Functional and Integrative Genomics, Campo Grande, C8 bdg, 1749-016 Lisboa, Portugal Available online 14 June 2014 Choose an option to locate/access this article: Check if you have access through your login credentials or your institution. Lumacaftor/ivacaftor combination therapy.

CF Centres. Nebulised Levofloxacin (Quinsair tm) Drug Development Pipeline. Orkambi, INN-lumacaftor & ivacaftor.